Episode
HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
- Podcast
- Breast Cancer Update
- Published
- Jun 29, 2026
- Duration seconds
- 5959
- Processing state
not_requested- Canonical source
- https://breast-oncology.captivate.fm/episode/6009-gmo26-hrposbc
Actions
POST https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/hr-positive-breast-cancer-fifth-annual-national-general-medical-oncology-summit/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/breast-cancer-update-757579/hr-positive-breast-cancer-fifth-annual-national-general-medical-oncology-summit.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00) Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40) Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57) Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00) CME information and select publications